<DOC>
	<DOCNO>NCT01380964</DOCNO>
	<brief_summary>The purpose study identify potential biomarkers diagnosis , disease progression assessment response treatment patient Duchenne Muscular Dystrophy .</brief_summary>
	<brief_title>Research Biomarkers Duchenne Muscular Dystrophy Patients</brief_title>
	<detailed_description />
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<criteria>FOR PATIENTS : Diagnosis DMD confirm genetic testing Age 3 year Weight 15 kg Informed consent sign FOR CONTROLS : Age 3 year Male gender Weight 15 kg Subjects national health insurance coverage Informed consent sign Nonacute chronic muscular , allergic , infectious , endocrine inflammatory disorder 3 week precede inclusion FOR PATIENTS : Concomitant chronic acute muscular , endocrine , infectious , allergic inflammatory disorder three week precede blood test Intake medicine angiotensinconverting enzyme inhibitor , beta blocker , dietary supplement , vitamin , alendronate methylphenidate . Steroids ( medicine prescribe calcium supplement proton pump inhibitor ) discuss Mental retardation autism Vaccination treatment immunoglobulin within three month precede inclusion FOR CONTROLS : Concomitant chronic acute muscular , neurological ( include mental retardation autism ) , infectious inflammatory disorder three week precede blood test Vaccination treatment immunoglobulin within three month precede inclusion</criteria>
	<gender>Male</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Duchenne Muscular Dystrophy</keyword>
	<keyword>biomarkers</keyword>
	<keyword>transcriptomics</keyword>
	<keyword>mironics</keyword>
	<keyword>proteomics</keyword>
</DOC>